Liting Chen

Dr. Liting Chen


Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
2 January 2020 in Blood
Verified
Journal Article
Closed access
PDF file
NWNa Wang
Na Wang
XHXuelian Hu
Xuelian Hu
WCWenyue Cao
Wenyue Cao
CLChunrui Li
Chunrui Li
YXYi Xiao
Yi Xiao
LHLiang Huang
Liang Huang
Relapse following chemeric antigen receptor (CAR) T-cell therapy can arise from progressive loss of the CAR T cells or from loss of the target antigen by tumor cells. Wang et al report that using a mix of CAR T cells targeting CD19 and CD22 reduces relapse with antigen-negative tumor cells. However, a lack of CAR T-cell persistence leads to increased relapse with antigen-positive cells.

27 May 2021 in Blood
Verified
Journal Article
Open access
PDF file
DWDi Wang
Di Wang
JWJue Wang
Jue Wang
GHGuang Hu
Guang Hu
WWWei Wang
Wei Wang
YXYi Xiao
Yi Xiao
JZJianfeng Zhou
Jianfeng Zhou
B-cell maturation antigen (BCMA)-specific chimeric antigen receptor (CAR) T-cell therapies have shown efficacy in relapsed/refractory multiple myeloma (RRMM). Because the non-human originated antigen-targeting domain may limit clinical efficacy, we developed a fully human BCMA-specific CAR, CT103A, and report its safety and efficacy in a phase 1 trial. Eighteen consecutive patients with RRMM, including 4 with prior murine BCMA CAR exposures, were enrolled. CT103A was administered at 1, 3, and 6 × 106 CAR-positive T cells/kg in the dose-escalation phase, and 1 × 106 CAR-positive T cells/kg in the expansion cohort. The overall response rate was 100%, with 72.2% of the patients achieving complete response or stringent complete response. For the 4 murine BCMA CAR–exposed patients, 3 achieved stringent complete response, and 1 achieved a very good partial response. At 1 year, the progression-free survival rate was 58.3% for all cohorts and 79.1% for the patients without extramedullary myeloma. Hematologic toxicities were the most common adverse events; 70.6% of the patients experienced grade 1 or 2 cytokine release syndromes. No immune effector cell–associated neurotoxicity syndrome was observed. To the cutoff date, CAR transgenes were detectable in 77.8% of the patients. The median CAR transgene persistence was 307.5 days. Only 1 patient was positive for the anti-drug antibody. Altogether, CT103A is safe and highly active in patients with RRMM and can be developed as a promising therapy for RRMM. Patients who relapsed from prior murine BCMA CAR T-cell therapy may still benefit from CT103A. This trial was registered at http://www.chictr.org.cn as #ChiCTR1800018137.

1 May 2020 in The Journal of Molecular Diagnostics
Verified
Journal Article
Closed access
YLYaoyao Lou
Yaoyao Lou
CCCaixia Chen
Caixia Chen
XLXiaolu Long
Xiaolu Long
JGJia Gu
Jia Gu
MXMin Xiao
Min Xiao
LCLiting Chen
Liting Chen

19 March 2020 in British Journal of Haematology
Verified
Journal Article
Open access
PDF file
XLXiaolu Long
Xiaolu Long
QXQian Xu
Qian Xu
YLYaoyao Lou
Yaoyao Lou
CLChunrui Li
Chunrui Li
JGJia Gu
Jia Gu
LCLiting Chen
Liting Chen
The British Journal of Haematology publishes original research papers in clinical, laboratory and experimental haematology. The Journal also features annotations, reviews, short reports, images in haematology and Letters to the Editor.

6 August 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ZWZhaofei Wang
Zhaofei Wang
JWJie Wang
Jie Wang
YZYuxuan Zhao
Yuxuan Zhao
JJJin Jin
Jin Jin
WSWentian Si
Wentian Si
PFPeng Fei
Peng Fei
Clarification of the cytotoxic function of T cells is crucial for understanding human immune responses and immunotherapy procedures. Here, we report a high-throughput Bessel oblique plane microscopy (HBOPM) platform capable of 3D live imaging and phenotyping of chimeric antigen receptor (CAR)-modified T-cell cytotoxicity against cancer cells. The HBOPM platform has the following characteristics: an isotropic subcellular resolution of 320 nm, large-scale scouting over 400 interacting cell pairs, long-term observation across 5 hours, and quantitative analysis of the Terabyte-scale 3D, multichannel, time-lapse image datasets. Using this advanced microscopy platform, several key subcellular events in CAR-T cells are captured and comprehensively analyzed; these events include the instantaneous formation of immune synapses and the sustained changes in the microtubing morphology. Furthermore, we identify the actin retrograde flow speed, the actin depletion coefficient, the microtubule polarization and the contact area of the CAR-T/target cell conjugates as essential parameters strongly correlated with CAR-T-cell cytotoxic function. Our approach will be useful for establishing criteria for quantifying T-cell function in individual patients for all T-cell-based immunotherapies.

4 March 2022 in Cytotherapy
Verified
Journal Article
Closed access
NYNan Yan
Nan Yan
NWNa Wang
Na Wang
GWGaoxiang Wang
Gaoxiang Wang
LHLiang Huang
Liang Huang
CLChunrui Li
Chunrui Li
YCYang Cao
Yang Cao